- - -

JOBS

EXECUTIVE JOBS

INVEST IN STOCKHOLM NEWSLETTER

SWEDISH WIRE NEWSLETTER

EMBASSIES/
CONSULATES
IN SWEDEN

RSS FEEDS

STOCKS

FLIGHTS, HOTELS AND HOLIDAYS

- - -
Investment opportunities

Tips from an insider: Five innovative tech startups

Tips from an insider: Stockholm tech start-ups

5 hot life science firms in Stockholm

Stockholm's top five infrastructure projects

Four Stockholm-based ICT firms to watch

Stockholm pioneers life science research

ICT startups offer investment opportunity

Swedish companies ready for exit

Five med-tech investment opportunities

Six cleantech investment opportunities

- - -
Rankings and surveys

Sweden tops English-language skills ranking

Sweden ranked world's best country to grow old

Swedish passport world's best for travellers

Sweden second best country for mothers

Stockholm climbs in competitiveness rankings

Sweden among best countries to be born

Fortune: 'Stockholm top place for startups'

Sweden tops first global Web Index

Sweden world's second most innovative country

Stockholm world's 6th 'best city'

'Cool Stockholm' most competitive Nordic capital

Sweden has (second) best reputation in the world

Sweden among top in Internet download speed

Sweden scores highest in 'Rule of law index'

Stockholm world's No1 in intellectual capital

Sweden the world's most ICT-competitive country

Sweden great place for moms – but Norway better

Swedes place 4th in English skills ranking

Sweden among top ICT countries

Sweden’s 10 greenest brands

‘Sweden needs to sell itself more’

Sweden overtakes the US in competitiveness

Sweden 10th ‘most admired country globally’

Sweden climbs in 'doing business' ranking

Sweden among world's least corrupt nations

Sweden's mortality rates world's second lowest

Sweden a good place to die – but Britain is best

Children in Sweden have best lives

Sweden the most competitive EU nation

Safe to do business with Swedes

How Sweden became an innovation frontrunner

Nordic countries world's most food-secure

Sweden the world’s best country – politically

Swedish firms among world's top brands

Swedish brands climb in global ranking

Sweden tops government ranking - while US lags 

'Swedish model' outranks 'American dream'  

Sweden among world's least corrupt nations

The Swedish Wire is a media production company that provides high-quality text, image and video content for international clients.

Xvivo Perfusion: XVIVO expands the NOVEL study in the USA

Press release published at The Swedish Wire
The University of Washington, Seattle, one of the major American lung transplant clinics, has been included in the American NOVEL study. It is the third clinic to have bought an XPS for this purpose. There continues to be great interest in the STEEN Solution? method and the XPS? in the USA.

XVIVO Perfusion AB (publ) was given approval by the FDA in the previous quarter to increase the number of centers in the ongoing NOVEL study in the USA. The participation of the University of Washington in Seattle in the NOVEL study will lead to more patients with lung disease now being able to receive a transplant.

The NOVEL trial was designed to safely increase the percentage of usable lungs from the donor pool. It is being performed at 8 centers in the USA. In the study, clinical outcomes after transplantation of lungs that have undergone warm perfusion after having been initially discarded are compared with a control group consisting of lungs that were initially assessed to be usable. Up until now 54 patients in the NOVEL study have received transplants after warm perfusion using the STEEN Solution? method. The results so far from the study indicate that lungs evaluated using STEEN Solution? in an XPS? do not differ in terms of safety and function from lungs transplanted directly. These results thus indicate that more donated lungs will be able to be used safely for transplantation, and this will benefit patients on the waiting list for new lungs. These results are consistent with those published from centers in Canada and Europe that have used STEEN Solution? clinically using an equivalent technique.

"We can see that there is growing interest in and outside the USA for the company's technology for warm perfusion using STEEN Solution? and XPS? as clinical experience becomes more widespread. It is exciting that leading clinics' interest is so great that they are investing considerable sums of money in equipment in order to be able to join the NOVEL study. They are doing so to be able to give transplants to more patients with severe lung disease," says Dr Magnus Nilsson, CEO of XVIVO Perfusion.

November 6, 2013
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion's business, please refer to the company's website, www.xvivoperfusion.com

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 6, 2013 at 11:00 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
This information was distributed by Cision
 

Latest Jobs for English speakers in Sweden

Banner

Jobs for English speakers in Sweden

Banner
Banner
Most Read Searched  
Banner
Banner
Banner